COMMUNIQUÉS West-GlobeNewswire

MediciNova Wins Contract Research and Development Innovation Award at 2025 BioTech Breakthrough Awards
07/11/2025
LA JOLLA, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875 [...]
Eledon Presents Phase 2 BESTOW Trial Results for Tegoprubart for the Prevention of Rejection in Kidney Transplantation at the American Society of Nephrology’s Kidney Week 2025 Annual Meeting
07/11/2025
Data from patients who remained on tegoprubart for a year post transplant showed an overall mean 12-month estimated glomerular filtration rate (eGFR) of approximately 69 mL/min/1.73 m² Tegoprubart demonstrated a [...]
Vafseo® (vadadustat) Dialysis Dependent Patient Post Hoc Data Analysis: Composite of All-Cause Mortality and Hospitalization Outcomes Statistically More Favorable for Patients Receiving Vadadustat vs. ESAs
07/11/2025
Win-Odds Analysis Presented at American Society of Nephrology Kidney Week 2025 CAMBRIDGE, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the [...]
Kelyniam Global Renews Licensing Agreement with Finceramica, Unlocking Access to Valuable Pipeline Products
07/11/2025
CANTON, Conn., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Kelyniam Global, Inc. (OTC: KLYG), a leading manufacturer of custom cranial and cranio-maxillofacial implants, today announced the renewal of its licensing agreement with [...]
Arvind Sood joins Coherus Oncology as Chief Strategy and Corporate Affairs Officer
06/11/2025
– Responsible for Corporate Development, Investor Relations, Government Affairs – REDWOOD CITY, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS), today announced that Arvind Sood has [...]
FDA Awards Second Batch of National Priority Vouchers
06/11/2025
Silver Spring, Md., Nov. 06, 2025 (GLOBE NEWSWIRE) -- The U.S. Food and Drug Administration today announced six additional awardees under the Commissioner’s National Priority Voucher (CNPV) pilot program . This second [...]
Intellia Therapeutics Announces Third Quarter 2025 Financial Results and Recent Updates
06/11/2025
Awaiting FDA clinical hold letter on MAGNITUDE and MAGNITUDE-2 clinical trials of nex-z Presenting longer-term Phase 1 clinical data of nex-z for ATTR-CM on November 10 at AHA 2025; previously published longer-term [...]
Denali Therapeutics Announces Board and Executive Leadership Updates
06/11/2025
SOUTH SAN FRANCISCO, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI) today announced updates to its Board of Directors and executive leadership team. Tim Van Hauwermeiren has been [...]
IN8bio Reports Third Quarter 2025 Financial Results and Recent Business Highlights
06/11/2025
Presented new preclinical data on INB-619, a novel gamma-delta (γδ) T cell engager (TCE), demonstrating equivalent potency comparable to FDA-approved commercial products with minimal adverse cytokine release, [...]
ORIC® Pharmaceuticals Announces Publication in Cancer Research on the Discovery and Development of Enozertinib, a Highly Selective, Brain-Penetrant EGFR Inhibitor
06/11/2025
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov. 06, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of [...]
Information relative au nombre total de droits de vote et d’actions composant le capital social au 20 octobre 2025
06/11/2025
Article R. 22-10-23 du Code de commerce Place de cotation : Euronext Paris Code ISIN / Mnémo : FR0013233012 / IVA Site web : www . i n v e n t i v a p ha r m a. c om Date Nombre de titres composant le capital en [...]
Statement of total voting rights and shares forming the company’s share capital as October 20, 2025
06/11/2025
Article R. 22-10-23 of the French Commercial Code Market : Euronext Paris ISIN code / Mnemo : FR0013233012 / IVA Web site : www . i n v e n t i v a p ha r m a. c om Date Number of Shares Outstanding Total voting rights [...]
Assemblée Générale Mixte du 27 novembre 2025 - Modalités de mise à disposition des documents préparatoires
06/11/2025
Daix (France), New York City (New York, Etats-Unis), le 6 novembre 2025 – Inventiva (Euronext Paris et NASDAQ : IVA) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisée dans le développement de [...]
Combined General Meeting of November 27, 2025 - Availability of the preparatory documents
06/11/2025
Daix (France), New York City (New York, United States), November 6, 2025 – Inventiva (Euronext Paris and Nasdaq : IVA) (“ Inventiva ” or the “ Company ”), a clinical-stage biopharmaceutical company focused on the [...]
Tectonic Therapeutic Announces Third Quarter 2025 Financial Results and Recent Business Highlights
06/11/2025
Positive topline data from Part B of the TX45 Phase 1b trial demonstrated improvements in both left heart function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with reduced [...]
Pacira BioSciences Reports Third Quarter 2025 Financial Results; Increases Full-year Gross Margin Guidance
06/11/2025
-- Third quarter revenues up 6% driven by EXPAREL volume growth of 9% -- -- Several key milestones advance 5x30 path to growth and value creation -- -- Conference call today at 4:30 p.m. ET -- BRISBANE, Calif., Nov. 06 [...]
aTyr Pharma Announces Third Quarter 2025 Results and Provides Corporate Update
06/11/2025
Results reported for Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis. Company plans to meet with the FDA to determine path forward for efzofitimod in pulmonary sarcoidosis in the first quarter of 2026. [...]
Denali Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights
06/11/2025
Tividenofusp alfa BLA review process for accelerated approval for MPS II continues with productive engagement with the FDA; commercial launch preparations on track DNL126 Phase 1/2 study enrollment completed, supporting [...]
Carlsmed Reports Third Quarter 2025 Financial Results and Raises Full-Year Guidance
06/11/2025
Third quarter revenue of $13.1 million, representing 98% growth YoY Raising full year 2025 revenue guidance to $49 million - $50 million CARLSBAD, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL [...]

Pages